Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment.

ABSTRACT:

Background

Recently approved second-generation androgen receptor inhibitors (SGARIs) for non-metastatic castration-resistant prostate cancer (nmCRPC) have similar efficacy but differ in safety profiles. We used a discrete choice experiment (DCE) to examine how nmCRPC patients and caregivers perceive the benefits versus risks of these new treatments.

Methods

An online DCE survey with 14 treatment choice questions was administered to nmCRPC patients and caregivers. Each choice question compared two hypothetical medication profiles varying in terms of 5 safety attributes (risk or severity of adverse events [AEs]: fatigue, skin rash, cognitive problems, serious fall, and serious fracture) and two efficacy attributes (duration of overall survival [OS] and time to pain progression

SUBMITTER: Srinivas S 

PROVIDER: S-EPMC7520320 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature